Modality
Multispecific
MOA
STINGag
Target
IL-17A
Pathway
PD-1/PD-L1
Atopic DermFL
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
Feb 2020
→ Jun 2030
Phase 1Current
NCT03655756
1,943 pts·FL
2020-02→2028-08·Terminated
NCT08478360
1,484 pts·FL
2022-02→2030-06·Not yet recruiting
3,427 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-07-133mo awayNDA· Atopic Derm
2028-08-282.4y awayPh2 Data· FL
2030-06-244.2y awayPh2 Data· FL
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1/2
Termina…
P1/2
Not yet…
Catalysts
NDA
2026-07-13 · 3mo away
Atopic Derm
Ph2 Data
2028-08-28 · 2.4y away
FL
Ph2 Data
2030-06-24 · 4.2y away
FL
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03655756 | Phase 1/2 | FL | Terminated | 1943 | PASI75 |
| NCT08478360 | Phase 1/2 | FL | Not yet recr... | 1484 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 |